Skip to main content
. 2021 Apr 10;10(4):867. doi: 10.3390/cells10040867

Figure 2.

Figure 2

Cell survival of hTERT-downregulated MCF7 (A) and MDA-MB-231 (B) cells after treatment with doxorubicin determined by MTT. Breast cancer cells were subjected to treatment with DOX on the 21st-day post-transduction. Data are presented as the mean ± standard deviation. (*) p < 0.05; (**) p < 0.01; (***) p < 0.001 relative to shRNA Control cells.